Skip to Content Skip to Content

Immunology

Deconstructing the mechanics of bone marrow disease
microscopic image of an immune cell labeled purple against a gray background

Acollaborative team developed an alginate-based hydrogel system that mimics the viscoelasticity of the natural extracellular matrix in bone marrow. By tweaking the balance between elastic and viscous properties in these artificial ECMs, they could recapitulate the viscoelasticity of healthy and scarred fibrotic bone marrow, and study the effects on human monocytes placed into these artificial ECMs. (Image: Adam Graham/Harvard CNS/Wyss Institute at Harvard University)

Deconstructing the mechanics of bone marrow disease

A new understanding of how mechanical features of bone marrow affect resident immune cells in a fibrotic cancer points to future therapeutic strategies for cancers and fibrotic diseases.

Katherine Unger Baillie

Regulating the regulators of the immune system
T cells labeled in fluorescent green patrol the vascular system, labeled in red

Regulating the regulators of the immune system

Research led by School of Veterinary Medicine scientists reveals a new layer of complexity with which the immune system finds a balance between controlling pathogens and protecting healthy tissue.

Katherine Unger Baillie

CAR T cells suppress GI solid tumor cells without toxicity to healthy tissue
Microscopic view of T cells.

CDH17 CAR T cells attack a tumor but spare healthy tissue. (Image: Penn Medicine News)

CAR T cells suppress GI solid tumor cells without toxicity to healthy tissue

New research finds that CAR T cells can eliminate solid tumors, but do not damage healthy, normal tissues that also express a tumor antigen, because the tumor antigen is sequestered and hidden between the normal cells.

Caren Begun

Decade-long remission after CAR T cell therapy
Two people stand closely together, smiling

Bill Ludwig, left, was the first patient to receive CAR T cells as part of clinical trials at Abramson Cancer Center. Carl June, right, has played a pioneering roll in the therapeutic use of CAR T cells. (Image: Penn Medicine)

Decade-long remission after CAR T cell therapy

Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.

Caren Begun